CoChat
Sign Up
Cited by 131Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol.

Open access
Miller, M, Seidler, A, Kwiterovich, P O, Pearson, T A·1992·Circulation
DOI 10.1161/01.cir.86.4.1165
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Patients with coronary artery disease (CAD) are at considerable risk for subsequent cardiovascular events. Although hyperlipidemia accentuates the risk, predictors of subsequent events with CAD and desirable total cholesterol (TC) (less than 5.2 mmol/l) have not been assessed. METHODS AND RESULTS: A survival analysis was performed in a subset of 740 consecutive patients who underwent diagnostic coronary arteriography between 1977 and 1978. Eight-three men and 24 women with angiographically documented CAD and desirable TC were followed for subsequent cardiovascular events, including myocardial infarction and cardiovascular death. Over a 13-year period, 75% of CAD subjects with reduced high density lipoprotein cholesterol (HDL-C) (less than 0.9 mmol/l) developed a subsequent cardiovascular event compared with 45% of those with HDL-C greater than or equal to 0.9 mmol/l (p = 0.002). A Kaplan-Meier analysis revealed significantly greater survival from cardiovascular end points in patients with baseline levels of HDL-C greater than or equal to 0.9 mmol/l (p = 0.005). After 11 variables were tested, an age-adjusted Cox proportional-hazards model identified two pairs of independent predictors of subsequent cardiovascular events: they were a left ventricular ejection fraction (LVEF) less than 35% (relative risk [RR], 6.5; 95% confidence interval [CI], 2.8, 15.3; p less than 0.001) and reduced HDL-C (RR, 2.0; 95% CI, 1.2, 3.3; p = 0.01) in the first model and LVEF less than 35% (RR, 6.5; 95% CI, 2.7, 15.6; p less than 0.001) and TC:HDL ratio greater than or equal to 5.5 (RR, 1.9; 95% CI, 1.1, 3.1; p = 0.02) in the second model. CONCLUSIONS: Low HDL-C (or high TC:HDL-C) is strongly predictive of subsequent cardiovascular events in subjects with CAD, despite desirable TC. As such, identification of this potentially modifiable risk factor should be actively pursued in this high-risk subgroup.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.86.4.1165

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. Rossouw JE, Lewis B, Rifkind BM: The value of lowering choles- terol after myocardial infarction. NEnglJMed 1990;323:1112-1119
  2. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering ther- apy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298
  3. Silverman KJ, Grossman W: Angina pectoris: Natural history and strategies for evaluation and management. N EnglJ Med 1984;310: 1712-1717
  4. The Coronary Drug Project Research Group: Natural history of myocardial infarction in the Coronary Drug Project: Long-term prognostic importance of serum lipid levels. Am J Cardiol 1978;42: 489-498
  5. Sparrow D, Dawber TR: The influence of cigarette smoking on prognosis after a first myocardial infarction: A report from the Framingham Study. J Chronic Dis 1978;31:425-432
  6. Goldbourt U, Cohen L, Neufeld HN: High density lipoprotein cholesterol: Prognosis after myocardial infarction: The Israeli Isch- emic Heart Disease Study. Int J Epidemiol 1986;15:51-55
  7. Dodds C, Mills GL: Influence of myocardial infarction on plasma lipoprotein concentration. Lancet 1959;1:1160-1163
  8. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LSC, McGoon DC, Murphy ML, Roe BB: A reporting system on patients evaluated for coronary artery disease. Circulation 1975;51: 5-40
  9. Kahn HA, Sempos CT: Statistical Methods in Epidemiology. New York, Oxford University Press, 1989, pp 168-206
  10. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cho- lesterol in adults. Arch Intern Med 1988;148:36-69
  11. Pryor DB, Harrell FE, Lee KL, Rosati RA, Coleman E, Cobb FR, Califf RM, Jones RH: Prognostic indicators for radionuclide angi- ography in medically treated patients with coronary artery disease. Am J Cardiol 1984;53:18-22
  12. Mulcahy R, Hickey N, Graham IM, MacAirt J: Factors affecting the 5-year survival rate of men following acute coronary heart disease. Am Heart J 1977;93:556-559
  13. Oberman A, Jones WB, Riley CP, Reeves TJ, Sheffield LT, Turner ME: Natural history of coronary artery disease. Bull N YAcad Med 1972;49:1109-1125
  14. Assmann G, Schulte H: The Prospective Cardiovascular Munster Study: Prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol 1987;59:9G-17G
  15. Abbott RD, Wilson PWF, Kannel WB, Castelli WP: High density lipoprotein cholesterol, total cholesterol and myocardial infarc- tion: The Framingham Study. Arteriosclerosis 1988;8:207-211
  16. Glueck CJ, Sanghvi VR, Laemmle P, Unger L, McCray C, Tracy T, Speirs J, Lang J, Tieger M, Kunkel R: Lack of concordance in classification of coronary heart disease risk: High-risk HDL cho- lesterol <35 mg/dl in subjects with desirable total serum choles- terol, <200 mg/dl. J Lab Clin Med 1990;116:377-385
  17. Romm PA, Green CE, Reagan K, Rackley CE: Relation of serum lipoprotein cholesterol levels to presence and severity of angio- graphic coronary artery disease. Am J Cardiol 1991;67:479-483
  18. Grundy S, Goodman DS, Rifkind BM, Cleeman JI: The place of HDL in cholesterol management: A perspective from the National Cholesterol Education Program. Arch Intern Med 1989;149: 505-510
  19. Eisenberg S: High density lipoprotein metabolism. J Lipid Res 1984;25:1017-1058
  20. Schaefer EJ: Clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency. Arteriosclerosis 1984;4:303-322
  21. Glueck CJ, Daniels SR, Bates S, Benton C, Tracy T, Third JLHC: Pediatric victims of unexplained stroke and their families: Familial lipid and lipoprotein abnormalities. Pediatrics 1982;69:308-316
  22. Bradby GVH, Valente AJ, Walton KW: Serum high-density lipo- proteins in peripheral vascular disease. Lancet 1978;2:1271-1274
  23. Barboriak JJ, Anderson AJ, Rimm AA, King JF: High density lipoprotein cholesterol and coronary artery occlusion. Metabolism 1979;28:735-737
  24. Rapp JH, Connor WE, Lin DS, Inahara T, Porter JM: Lipids of human atherosclerotic plaques and xanthomas: Clues to the mech- anism of plaque progression. J Lipid Res 1983;24:1329-1335
  25. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr: Inverse relationship between blood levels of high density lipoprotein sub- fraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 1983;80:1449-1453
  26. Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwitero- vich P, Wacholder S, Sniderman A: The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. N Engl J Med 1984;311:1329-1332
  27. Sniderman A, Wolfson C, Teng B, Franklin F, Bachorik PS, Kwiterovich PO: Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 1982;97:833-839
  28. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607
  29. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C: Serum prostacyclin stabilizing factor is identical to apolipoprotein A-i: A novel function of apo A-1. J Clin Invest 1988;82:803-807
  30. Aoyama T, Yui Y, Morishita H, Kawai C: Prostaglandin 12 half-life regulated by high density lipoprotein is decreased in acute myo- cardial infarction and unstable angina pectoris. Circulation 1990; 81:1784-1791
  31. Mensink RP, Katan MB: Effect of a diet enriched with monoun- saturated or polyunsaturated fatty acids on levels of low density and high density lipoprotein cholesterol in healthy men and women. N Engl J Med 1989;317:1237-1245
  32. Ornish D, Brown SE, Scherwitz LW, Ornish D, Brown SE, Scher- witz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL: Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129-133
  33. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Hein- salmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Maen- paa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pik- karainen J, Romo M, Sjoblom T, Nikkila EA: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651
  34. Brown MS, Goldstein JL: A receptor mediated pathway for cho- lesterol homeostasis. Science 1986;232:34-47
  35. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the choles- terol-fed rabbit. J Clin Invest 1990;85:1234-1241
  36. Rubin EM, Krauss RM, Spangler E, Verstuyft JG, Clift SM: Inhi- bition of early atherogenesis in transgenic mice by human apolipo- protein A-1. Nature 1991;253:265-267

Cited by

Sorted by citations

Related

Authors
Miller, M., Seidler, A., Kwiterovich, P. O., & Pearson, T. A.
Affiliations
Johns Hopkins University (US)
ORCID
Miller, M
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1992-10
Volume
86
Issue
4
Pages
1165-1170
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/01.cir.86.4.1165
OpenAlex
W2001802117
Cited by
131
References
10
Citations by year
2023: 1 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 2
FWCI
11.25
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (1f32hl007596-01, 5k07hl002263-04)
  • National Heart, Lung, and Blood Institute (5F32HL07596, KO7 HL-02263-03)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
coronary artery disease, cardiovascular events, HDL cholesterol, total cholesterol, TC/HDL-C ratio, left ventricular ejection fraction, cardiovascular risk prediction, myocardial infarction, cardiovascular mortality, hyperlipidemia, risk factors, long-term prognosis, coronary angiography follow-up, modifiable risk factors
MeSH terms
Adult, Cardiovascular Diseases, Cholesterol, Coronary Disease, Female, Forecasting, Humans, Lipids, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Male, Risk Factors, Time Factors, Triglycerides, Proportional Hazards Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review